Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fusion Pharmaceuticals Inc. - Common Shares (NQ: FUSN )

21.55 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fusion Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 Next >
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Top 4 Health Care Stocks That May Plunge This Month
Via Benzinga
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA... 
Via Benzinga
Exposures Product Safety
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
Recap: Fusion Pharmaceuticals Q4 Earnings
Via Benzinga
Unveiling 11 Analyst Insights On Fusion Pharmaceuticals
Via Benzinga
Kuehn Law Encourages FUSN, KAMN, DRQ, and VZIO Investors to Contact Law Firm
--News Direct-- 
Via News Direct
FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. The Dow traded up 0.63% to 39,034.59 while the NASDAQ rose 0.35% to 16,160.20. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
Via Benzinga
A Glimpse Into The Expert Outlook On Fusion Pharmaceuticals Through 7 Analysts
Via Benzinga
Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 200 points on Tuesday. The Dow traded up 0.54% to 39,001.22 while the NASDAQ fell 0.34% to 16,048.51. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Down 100 Points; US Housing Starts Surge In February
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover
The company is working on radiopharmaceuticals treatments for cancer. 
Via Investor's Business Daily
Why Is Greenwave Tech Solutions (GWAV) Stock Down 53% Today?
Greenwave Tech Solutions stock is falling on Tuesday following an update on warrants for GWAV stock and other news this morning. 
Via InvestorPlace
Nvidia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Is Ontrak (OTRK) Stock Up 105% Today?
Ontrak stock is on the rise Tuesday as OTRK investors are excited about an upcoming live fireside chat set for later today. 
Via InvestorPlace
Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Shares of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) rose sharply in today’s pre-market trading after the company agreed to be acquired by AstraZeneca for around $2 billion in cash. 
Via Benzinga
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?
Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3. 
Via InvestorPlace
US Stocks Poised For Lower Open As Fed Jitters Dampen Tech Hopes; Oil Rally Pauses, Bitcoin Slides 8%
Interest-rate concerns seem to be impacting market sentiment as stock futures indicate a slightly lower opening on Tuesday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning! 
Via InvestorPlace
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
7 Low-Cost Call Options With High-Profit Potential
Call options are exciting but they can be a bit confusing. Let me guide you to compelling opportunities among certain hot names. 
Via InvestorPlace
Fusion Pharmaceuticals - Already Discovered By Wall Street
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.